Yuji Kojima
Ise, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Journal: Journal of medical virology
Published: May 22, 2022
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: March 24, 2022
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Journal: Journal of viral hepatitis
Published: March 03, 2022
Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: January 17, 2022
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: November 08, 2021
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Journal: Hepatology communications
Published: October 22, 2021
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Journal: Journal of medical virology
Published: June 13, 2021
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Journal: Cancers
Published: March 14, 2021
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 15, 2020
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
Journal: Scientific reports
Published: January 21, 2020
Changing clinical and molecular characteristics of hepatitis E virus infection in Mie Prefecture, Japan: Disappearance of indigenous subtype 3e strains.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: February 24, 2019
Last Updated: 09/26/2026